 Home > Medical News > Latest Medical News > Amgen's lipid-lowering drug Repatha receives FDA approval to treat children with HeFH cholesterol disease

Amgen's lipid-lowering drug Repatha receives FDA approval to treat children with HeFH cholesterol disease

 Last Update: 2021-10-22
 Source: Internet
 Author: User

Tags

mals disease

non examples density

1 year subscription

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

CompilationFan Dongdong

A few days ago, the FDA announced that it would approve the use of Amgen’s PCSK9 inhibitor Repatha as an additional treatment for dietary adjustments and statins for the treatment of pediatric patients 10 years of age and older with heterozygous familial hypercholesterolemia (HeFH).

The FDA's approval of Repatha is mainly based on the Phase 3b HAUSER-RCT safety and effectiveness study in children with HeFH aged 10 to 17 years

HeFH is a genetic disease that affects one in every 250 people worldwide

Amgen Repatha is a human monoclonal immunoglobulin G2 (IgG2) that can target PCSK9 in patients and inhibit the binding of circulating PCSK9 to low-density lipoprotein (LDL) receptors (LDLR), thereby preventing PCSK9-mediated The degradation of LDLR allows LDLR to recirculate back to the surface of liver cells, thereby reducing the level of LDL-C in the patient's body

Repatha and Praluent were approved for marketing in 2015, and both focused on PCSK9 protein

However, the two drugs performed mediocre after they went on the market

In the future, as Novartis inclisiran is expected to be approved for this indication as expected, the two drugs may face new competitive threats

Reference source:

Amgen's Repatha gains an edge on rival Praluent with FDA approval to treat children with rare cholesterol condition

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

jobs united states(236)

united states jobs(223)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

ups united states(221)

announcements today(81)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.